Sona Nanotech Inc.’s Post

Sona Nanotech Closes Private Placement Financing to Raise $1,500,000 in Gross Proceeds and Announces Additional Financing. Read the full press release here: https://bit.ly/3MTAACh #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Sona Nanotech Inc. is pleased to announce that it plans to raise up to $1,500,000 through a private placement financing of up to 6,000,000 common shares of Sona at a price of $0.25 per Share. Insiders and certain other existing shareholders of Sona may also subscribe for Shares under the Financing.   Read the full press release here: https://bit.ly/4d0JAAX #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Sona Nanotech provides a replay of their recent webinar describing their success with preclinical cancer treatment trials. Watch the full CanAm Physician Recruiting Inc. webinar here: https://lnkd.in/eMjRqhQs #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

If you missed our investor webinar, you can watch the replay below to learn about the efficacy study results for Sona's Targeted Hyperthermia Therapy (THT) and its potential to revolutionize cancer treatment. CEO, David Regan, CMO Dr. carman giacomantonio, and CSO Len Pagliaro discussed the recent results from Sona’s preclinical melanoma studies as well as how a vaccine-like effect was achieved. Watch the full webinar replay here: https://lnkd.in/efADjCnZ #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Learn how Sona’s THT therapy achieved a vaccine effect, inhibiting the growth of secondary melanoma tumors in their preclinical efficacy study by joining us for a webinar today at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment therapy, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT therapy, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Sona observes a 'vaccine effect' in pre-clinical melanoma study in which new tumor growth was inhibited. Beyond shrinking tumors on its own, Sona’s Targeted Hyperthermia Therapy also stimulated innate immune systems to target and inhibit untreated tumors when combined with a standard immunotherapeutic drug, IL-2. The detailed biomarker and gene expression analysis indicates this was achieved via a lasting activation of the innate immune system. Read the full press release here: https://bit.ly/4c8iR4R #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Join CEO, David Regan, CMO Dr carman giacomantonio, and CSO Len Pagliaro for an exclusive webinar tomorrow at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment therapy, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT therapy, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Join CEO, David Regan, CMO Dr carman giacomantonio, and CSO Len Pagliaro for an exclusive webinar on 26 June at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment technology, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT technology, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Sona Nanotech Inc. is pleased to announce that its targeted hyperthermia therapy demonstrated positive results with a second cancer type in its preclinical efficacy study. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona’s THT achieved responses in a preclinical melanoma model similar to those from its recently reported triple negative breast cancer study. Read the full news release here: https://bit.ly/4c8n9cx #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

Earlier today, Sona Nanotech's CMO, Dr. carman giacomantonio, presented Sona's preclinical efficacy study at the STING & TLR-Targeted Therapies Summit. This conference explores strategies to precisely target and activate innate immune pathways, aiming to unlock new avenues for improved, personalized cancer therapies with optimal safety and efficacy. We look forward to sharing some snippets from his session:  https://lnkd.in/efnTJBA #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology #stingmodel